Al-Modawat Specialized Medical (9594) fair value: what the stock is really worth
As of Oct 29, 2026: fair value (intrinsic value) of Al-Modawat Specialized Medical stock SAR 4.73, price SAR 3.80, upside +24.4%, quality 44 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 28, 2026.
How to read this chart
32‑month range 3.09 SAR – 972,709 SAR · fair‑value band 3.55 SAR – 5.91 SAR · the 3.80 SAR price screens below the 4.73 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 28, 2026.
Follow Al-Modawat Specialized Medical in your weekly email
Every Wednesday you see whether Al-Modawat Specialized Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Al-Modawat Specialized Medical Company operates a general hospital in the Kingdom of Saudi Arabia. The company was founded in 2014 and is headquartered in Muhayil, Saudi Arabia.
Stock analysis
Al-Modawat Specialized Medical (9594) currently trades at 3.80 SAR, while our model-based Fair Value estimate is 4.73 SAR, implying the stock looks roughly 19.6% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 11.31 SAR per share, and 11 of the 16 models we run sit above the 3.80 SAR price.
Bear case: the Economic Profit group reads lowest at 2.00 SAR, and 5 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 3.55 SAR (bear) to 5.91 SAR (bull), the price of 3.80 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Al-Modawat Specialized Medical reported revenue of 122M SAR in FY2025 versus 40.8M SAR in FY2021, a compound +31.4%/yr. Reported net income was 19.0M SAR in FY2025.
Key figures
Market cap 295M SAR (≈ $78.6M) Micro · P/E ratio 19.0 · P/S ratio 2.12 · EPS (TTM) 0.2000 SAR · Net margin 10.6% · Return on equity 16.7% · Return on assets (EBIT) 12.5% · Operating margin 12.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 24%, 9594 screens cheaper than that median.
Fair Value models
Bear3.55 SARFair Value 4.73 SARBull5.91 SAR
Price 3.80 SAR · Upside +24.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.1660 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV2.25 SAR2.52 SAR2.73 SAR70
Residual Income1.42 SAR2.00 SAR3.59 SAR69
ROIC Compounder2.81 SAR4.00 SAR4.86 SAR67
All 16 models by family
Earnings-Based
Graham-Dodd1.81 SAR12.63 SAR17.72 SAR60
Lynch FV5.84 SAR8.34 SAR10.84 SAR58
PEG = 1.05.84 SAR8.34 SAR10.84 SAR55
EPV2.25 SAR2.52 SAR2.73 SAR70
Dividend Discount
Gordon GGM0.2900 SAR0.5000 SAR0.6700 SAR65
DDM Multi-Stage0.2900 SAR0.4700 SAR0.5400 SAR65
Multiples
P/E Multiple4.39 SAR5.86 SAR7.32 SAR63
P/S Multiple3.40 SAR4.53 SAR5.66 SAR58
P/B Multiple4.17 SAR5.56 SAR6.95 SAR55
EV/EBIT3.94 SAR5.25 SAR6.57 SAR63
EV/EBITDA4.46 SAR5.94 SAR7.43 SAR64
EV/Revenue2.81 SAR4.01 SAR5.22 SAR51
Asset-Based
NCAV (Graham)0.1100 SAR0.1600 SAR0.2000 SAR52
Economic Profit
Residual Income1.42 SAR2.00 SAR3.59 SAR69
ROIC Compounder2.81 SAR4.00 SAR4.86 SAR67
Growth Earnings
Growth-Adj P/E7.92 SAR11.31 SAR14.71 SAR65
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+61.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.7%
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−22.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−22.2%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−2% → 18%
Compare Al-Modawat Specialized Medical with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 242 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score44 · Bottom 25%
Fair Value upside+24.4% · Above median
Profitability
Return on equity (12 months)16.7% · Top 25%
Return on assets11.8% · Top 25%
Net margin (12 months)10.6% · Above median
Operating margin (12 months)12.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)41.1% · Top 25%
Dividend yield (12 months)0.0% · Bottom 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Al-Modawat Specialized Medical Fair Value". https://www.fairvalue-calculator.com/stock/9594
Frequently asked questions
Is Al-Modawat Specialized Medical (9594) overvalued or undervalued?
As of Oct 28, 2026, our model estimates a fair value of 4.73 SAR versus a price of 3.80 SAR, about +24% upside (undervalued).
What is the fair value of 9594?
Our model-based fair value for Al-Modawat Specialized Medical is 4.73 SAR (as of Oct 28, 2026), built from audited fundamentals. The current price: 3.80 SAR.
What is the quality score of 9594?
Al-Modawat Specialized Medical has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Al-Modawat Specialized Medical (9594)?
Our model-based price target is the fair value of 4.73 SAR (as of Oct 28, 2026) from 16 valuation models. Cautious scenario 3.55 SAR, optimistic scenario 5.91 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Al-Modawat Specialized Medical stock forecast for 2026?
Our models put fair value at 4.73 SAR, about +24% upside versus a price of 3.80 SAR (undervalued). Cautious scenario 3.55 SAR, optimistic scenario 5.91 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Al-Modawat Specialized Medical (9594)?
Al-Modawat Specialized Medical reported trailing-twelve-month revenue of about 139M SAR (latest available figure, as of Oct 28, 2026).
What is the intrinsic value of Al-Modawat Specialized Medical (9594)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Al-Modawat Specialized Medical it is 4.73 SAR per share (as of Oct 28, 2026), against a price of 3.80 SAR. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Al-Modawat Specialized Medical stock overvalued or undervalued in 2026?
As of Oct 28, 2026, 9594 trades below its calculated fair value: price 3.80 SAR, fair value 4.73 SAR, a gap of about +24% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9594?
No. The price is what the market pays today (3.80 SAR); the fair value is what the company's own numbers justify (4.73 SAR). For Al-Modawat Specialized Medical the two are 0.9260 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Al-Modawat Specialized Medical worth?
The market values Al-Modawat Specialized Medical at about 295M SAR (market capitalisation, as of Oct 28, 2026). Per share that is 3.80 SAR; our models calculate a fair value of 4.73 SAR per share.
What do the bullish and bearish scenarios say about 9594?
Our models span a range for Al-Modawat Specialized Medical: cautious scenario 3.55 SAR, base 4.73 SAR, optimistic 5.91 SAR per share (as of Oct 28, 2026, price 3.80 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9594?
Al-Modawat Specialized Medical trades at a price-to-earnings ratio of 19.0 (as of Oct 28, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 4.73 SAR is built from several models across several years. Other multiples: P/B 3.3, P/S 2.1, EV/EBITDA 10.9.
How solid is the balance sheet of Al-Modawat Specialized Medical (9594)?
Balance-sheet figures for Al-Modawat Specialized Medical (as of Oct 28, 2026): return on equity 16.7%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 9594 from its 52-week high?
Al-Modawat Specialized Medical trades at 3.80 SAR, about 33% below its 52-week high of 5.65 SAR and 22% above the low of 3.11 SAR (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of 4.73 SAR is for.
Which stocks are comparable to Al-Modawat Specialized Medical?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Al-Modawat Specialized Medical stock attractive at the current price?
The data as of Oct 28, 2026: price 3.80 SAR, calculated fair value 4.73 SAR (+24%), Quality Score 44/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9594 calculated?
We run Al-Modawat Specialized Medical through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4.73 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. Al-Modawat Specialized Medical currently trades 20 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Al-Modawat Specialized Medical (9594)?
The closing price on Oct 29, 2026 was 3.80 SAR. Our model-based fair value is 4.73 SAR, about +24% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Al-Modawat Specialized Medical right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Al-Modawat Specialized Medical
How large is the market capitalisation of Al-Modawat Specialized Medical (9594)?
The market capitalisation of Al-Modawat Specialized Medical is 295M SAR (≈ $78.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Al-Modawat Specialized Medical (9594)?
The price-to-sales ratio of Al-Modawat Specialized Medical is 2.12 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Al-Modawat Specialized Medical (9594)?
Earnings per share at Al-Modawat Specialized Medical are 0.2000 SAR (price ÷ EPS = P/E 19.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Al-Modawat Specialized Medical (9594)?
The net margin of Al-Modawat Specialized Medical is 10.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Al-Modawat Specialized Medical (9594)?
The return on equity (ROE) of Al-Modawat Specialized Medical is 16.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Al-Modawat Specialized Medical (9594)?
On an EBIT basis the return on assets of Al-Modawat Specialized Medical is 12.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Al-Modawat Specialized Medical (9594)?
The operating margin of Al-Modawat Specialized Medical is 12.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Al-Modawat Specialized Medical (9594)?
Revenue at Al-Modawat Specialized Medical is growing +41.1% versus a year earlier (3y avg +27.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Al-Modawat Specialized Medical (9594)?
Earnings per share at Al-Modawat Specialized Medical are growing −34.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Al-Modawat Specialized Medical (9594) generate?
The free cash flow of Al-Modawat Specialized Medical is −17.1M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Al-Modawat Specialized Medical (9594) carry?
The net debt of Al-Modawat Specialized Medical is 569K SAR (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Al-Modawat Specialized Medical in the live analysis
One click puts Al-Modawat Specialized Medical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 28, 2026